| Size | Price | |
|---|---|---|
| 10g | ||
| 50g | ||
| Other Sizes |
| ln Vitro |
As the concentration of CV in the growing medium grew, so did strain RB1's sensitivity to streptomycin. Cytochrome aa3 levels and streptomycin sensitivity both rise with increasing CV concentration in the growing medium. B. subtilis cannot accumulate streptomycin without cytochrome aa3 [1]. Streptomycin has an impact on tRNA selection. Mutations causing streptomycin resistance often localize to protein S12, and the majority of these variations show increased discrimination during tRNA selection [2].
|
|---|---|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Similar to other aminoglycoside antibiotics, Streptomycin is rarely excreted into breast milk. Newborns appear to absorb small amounts of aminoglycoside antibiotics, but their serum concentrations are far lower than those achieved when treating neonatal infections, making systemic effects of Streptomycin unlikely. Even smaller amounts of Streptomycin are expected to be absorbed by older infants. Monitoring for potential effects on the infant's gut microbiota, such as diarrhea, candidiasis (e.g., thrush, diaper rash), or rare hematochezia (blood in stool), which may indicate antibiotic-associated colitis, should be conducted. ◉ Effects on Breastfed Infants No relevant published information was found as of the revision date. ◉ Effects on Lactation and Breast Milk An observational study found that Streptomycin did not inhibit lactation. |
| References | |
| Additional Infomation |
According to state or federal labeling requirements, Streptomycin sulfate may cause developmental toxicity. Streptomycin sulfate (2:3) (salt) is an antibacterial agent. It is a white to light gray or pale yellow powder with a slightly amine odor. Streptomycin sulfate is an aminoglycoside sulfate. Its function is related to Streptomycin. Streptomycin sulfate is the sulfate form of Streptomycin, an aminoglycoside antibiotic derived from Streptomyces griseus with antibacterial properties. Streptomycin sulfate binds to the S12 protein of the bacterial 30S ribosomal subunit, thereby inhibiting peptide chain elongation and protein synthesis, ultimately leading to bacterial cell death. It is an antibiotic produced by the soil actinomycete Streptomyces griseus. It works by inhibiting the initiation and elongation steps in protein synthesis. See also: Streptomycin (containing the active moiety)... See more...
|
| Exact Mass |
1456.433
|
|---|---|
| CAS # |
3810-74-0
|
| Related CAS # |
Streptomycin;57-92-1
|
| PubChem CID |
19648
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
948.2ºC at 760 mmHg
|
| Flash Point |
527.3ºC
|
| Index of Refraction |
-85 ° (C=1, H2O)
|
| Hydrogen Bond Donor Count |
30
|
| Hydrogen Bond Acceptor Count |
42
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
95
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
30
|
| SMILES |
S(=O)(=O)(O[H])O[H].S(=O)(=O)(O[H])O[H].S(=O)(=O)(O[H])O[H].O([C@@]1([H])[C@@]([H])([C@@](C([H])=O)([C@]([H])(C([H])([H])[H])O1)O[H])O[C@@]1([H])[C@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])O[H])O1)O[H])O[H])N([H])C([H])([H])[H])[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@]([H])([C@]1([H])/N=C(\N([H])[H])/N([H])[H])O[H])/N=C(\N([H])[H])/N([H])[H])O[H])O[H].O([C@@]1([H])[C@@]([H])([C@@](C([H])=O)([C@]([H])(C([H])([H])[H])O1)O[H])O[C@@]1([H])[C@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])O[H])O1)O[H])O[H])N([H])C([H])([H])[H])[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@]([H])([C@]1([H])/N=C(\N([H])[H])/N([H])[H])O[H])/N=C(\N([H])[H])/N([H])[H])O[H])O[H]
|
| InChi Key |
QTENRWWVYAAPBI-YCRXJPFRSA-N
|
| InChi Code |
InChI=1S/2C21H39N7O12.3H2O4S/c2*1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35;3*1-5(2,3)4/h2*4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28);3*(H2,1,2,3,4)/t2*5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+;;;/m00.../s1
|
| Chemical Name |
2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;sulfuric acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~137.23 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (137.23 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00004444 | COMPLETED | Drug: paromomycin Drug: streptomycin |
Tuberculosis, Pulmonary | FDA Office of Orphan Products Development | 1994-11 | Not Applicable |
| NCT00128466 | COMPLETED | Drug: gentamicin Drug: streptomycin |
Plague | Centers for Disease Control and Prevention | 2004-08 | Phase 2 Phase 3 |
| NCT01432925 | COMPLETED | Procedure: surgical intervention on Buruli ulcer | Buruli Ulcer Mycobacterium Ulcerans Disease |
University Medical Center Groningen | 2011-09 | Not Applicable |
| NCT04110340 | RECRUITING | Drug: Ciprofloxacin Drug: Streptomycin Drug: Gentamicin |
Plague, Bubonic Plague, Pneumonic |
University of Oxford | 2020-02-15 | Phase 3 |
| NCT02604849 | COMPLETED | Drug: Neomycin Drug: Streptomycin Drug: Gentamicins |
Patients Colonized by Klebsiella Pneumoniae |
Maimónides Biomedical Research Institute of Córdoba | 2012-07 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
